文献速递类风湿关节炎

类风湿关节炎中IL6R阻断剂治疗反应的预测

Predicting treatment response to IL6R blockers in rheumatoid arthritis.
PubMed 文献 · Rheumatology (Oxford) · 2020-01-01

本文综述了预测类风湿关节炎(RA)患者对IL6R阻断剂治疗反应的生物标志物研究现状。目前研究成功有限,但血清药物水平和低ICAM1水平在独立研究中显示出希望。文章还讨论了研究者面临的挑战及从TNF抑制剂研究中吸取的教训。

要点

  • 40%的RA患者对bDMARDs不能达到完全疾病控制。
  • 血清药物水平和低ICAM1水平与IL6R阻断剂反应相关。
  • 需借鉴TNFi研究经验以推动IL6R阻断剂预测标志物研究。

核心结论

  • 血清药物水平和低ICAM1水平是有望预测IL6R阻断剂治疗反应的生物标志物。

研究设计与样本

  • 本文为综述,回顾了预测IL6R阻断剂治疗反应的生物标志物研究现状。

主要发现

  • 目前识别IL6R阻断剂反应预测标志物的研究成功有限。
  • 血清药物水平和低ICAM1水平在独立研究中与治疗反应相关。

临床怎么用

  • 血清药物水平和低ICAM1水平可能有助于识别对IL6R阻断剂有反应的患者。

局限性

  • 目前预测IL6R阻断剂反应的生物标志物研究成功有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with severe, active RA who have not responded to conventional therapy may receive biological disease modifying anti-rheumatic drugs (bDMARDs). However, 40% of cases do not achieve complete disease control, resulting in a negative impact on patient quality of life and representing a waste of healthcare resources. Ongoing research seeks to establish biomarkers, which can be used to predict treatment response to biologics in RA to enable more targeted approaches to treatment. However, much of the work has focused on one class of biologic drug, the TNF inhibitors (TNFi). Here, we will review the current state of research to identify biomarkers predictive of response to the class of bDMARDs targeting the IL6R. While success has been limited thus far, serum drug and low ICAM1 levels have shown promise, with associations reported in independent studies. The challenges faced by researchers and lessons learned from studies of TNFi will be discussed.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Nouri B, Nair N, Barton A, et al. Predicting treatment response to IL6R blockers in rheumatoid arthritis. Rheumatology (Oxford). 2020. PMID: 32864695. doi:10.1093/rheumatology/keaa529

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。